The companies anticipate finalising the acquisition in the third quarter of 2026.

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and ...

In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...

Edgewise Therapeutics (EWTX) stays a Buy after its $2.65B Servier deal funds EDG-7500 for HCM with key Q2 2026 data. Read ...

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...

By Siddhi Mahatole and Bhanvi Satija June 1 (Reuters) - Edgewise Therapeutics on Monday agreed to sell its muscular dystrophy drug and related business to Servier in a deal worth up to $2.65 billion, ...

France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a ...

The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say ...

Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...

SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

For Duchenne and Becker muscular dystrophies, muscle biopsy may show whether dystrophin, a muscle protein, is missing or abnormal, and DNA testing is used to analyze the condition of the related gene.